Wall Street analysts expect that China Biologic Products, Inc. (NASDAQ:CBPO) will report earnings of $1.36 per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings of $1.10 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 23.6%. The firm is expected to announce its next earnings report on Thursday, August 3rd.
On average, analysts expect that China Biologic Products will report full-year earnings of $4.85 per share for the current year. For the next financial year, analysts forecast that the firm will post earnings of $5.95 per share, with EPS estimates ranging from $5.88 to $6.02. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover China Biologic Products.
A number of equities analysts recently commented on the stock. Goldman Sachs Group, Inc. (The) assumed coverage on shares of China Biologic Products in a research report on Tuesday, May 30th. They set a “neutral” rating on the stock. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of China Biologic Products in a research report on Monday, June 12th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 price target on shares of China Biologic Products in a research report on Friday, March 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $132.00.
In other news, insider Zhijing Cbpo Liu sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total value of $873,675.00. Following the sale, the insider now directly owns 10,969 shares in the company, valued at approximately $1,277,778.81. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.73% of the company’s stock.
A number of large investors have recently bought and sold shares of CBPO. Vontobel Asset Management Inc. acquired a new stake in China Biologic Products during the first quarter valued at approximately $5,735,000. Copper Rock Capital Partners LLC increased its stake in China Biologic Products by 26.7% in the first quarter. Copper Rock Capital Partners LLC now owns 30,855 shares of the biopharmaceutical company’s stock valued at $3,086,000 after buying an additional 6,495 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in China Biologic Products during the fourth quarter valued at approximately $3,086,000. UBS Asset Management Americas Inc. increased its stake in China Biologic Products by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 181,287 shares of the biopharmaceutical company’s stock valued at $19,492,000 after buying an additional 3,217 shares in the last quarter. Finally, Norges Bank acquired a new stake in China Biologic Products during the fourth quarter valued at approximately $24,340,000. Institutional investors and hedge funds own 74.28% of the company’s stock.
Shares of China Biologic Products (NASDAQ:CBPO) traded up 0.15% on Monday, reaching $112.57. 143,721 shares of the company traded hands. The stock has a 50 day moving average of $112.46 and a 200 day moving average of $109.57. China Biologic Products has a 52-week low of $96.99 and a 52-week high of $137.38. The stock has a market cap of $3.06 billion, a price-to-earnings ratio of 29.16 and a beta of 1.73.
China Biologic Products Company Profile
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/zacks-analysts-expect-china-biologic-products-inc-cbpo-will-announce-earnings-of-1-36-per-share/1932230.html
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.